MI-463 is primarily researched for its potential in cancer therapy, particularly in targeting specific proteins involved in cancer cell growth and survival. It has shown promise in preclinical studies as an inhibitor of menin-MLL interactions, which are critical in certain types of leukemia, such as acute myeloid leukemia (AML) and mixed lineage leukemia (MLL). By disrupting these interactions, MI-463 may help to halt the proliferation of cancer cells and induce apoptosis, making it a candidate for further development in targeted cancer treatments. Additionally, its application extends to studying molecular pathways in oncology, aiding in the understanding of disease mechanisms and the development of novel therapeutic strategies.